4
Changes in Ownership
RECURSION PHARMACEUTICALS, INC. Filed Acc 0001628280-25-004086
Chief R&D Commercial Officer gave up 2,753 shares (to pay taxes)
- Chief R&D Commercial Officer acquired 218,162 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
Khan Najat · Chief R&D Commercial Officer
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-02-03 | Grant or award : show line 1 in the form | +210,113 | 707,085 | D | ||
| 2025-02-03 | Grant or award : show line 2 in the form | +8,049 | 715,134 | D | ||
| 2025-02-03 | Shares withheld for taxes : show line 3 in the form | −2,753 | $7.25 | $19,959 | 712,381 | D |
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2025-02-03 | Grant or award : show line 4 in the form Stock Option (Right to Buy) | +420,226 | 420,226 | D |
Loading xslF345X05/wk-form4_1738792220.xml…